NUMIF News and Press, Numinus Wellness Inc. From 10/03/23

Numinus Announces Psychedelic Program for Mental Distress Associated with Chronic and Serious Illness through Cedar Clinical Research Canada NewsWire VANCOUVER, BC , Oct. 3, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: ...

2023-09-26 06:31:11 ET More on Numinus Wellness Seeking Alpha’s Quant Rating on Numinus Wellness Historical earnings data for Numinus Wellness Financial information for Numinus Wellness Numinus Wellness Inc. (NUMIF) Q3 2023 Earnings Call Transcript ...

Numinus Wellness Inc. Announces At-The-Market Offering Equity Program Canada NewsWire VANCOUVER, BC , Sept. 25, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF), is pleased to announce that it has established an at-the-ma...

Numinus Congratulates MAPS on its Phase 3 Study Results Published in Nature Medicine Canada NewsWire Study Results are widely regarded as the final step before MDMA-assisted therapy is reviewed by the FDA for wider patient access. Numinus continues to support grea...

Numinus Takes Actions to Accelerate its Path to Profitability by Focusing on Positive Cash Flow Generating Operations Canada NewsWire The Company is ceasing operating activities at Numinus Bioscience – its non-revenue producing research lab, and is consolidating clinic ...

2023-09-16 16:00:56 ET On Sept. 14, the Multidisciplinary Association for Psychedelic Studies ("MAPS") announced positive results on a second phase 3 trial for MDMA -- also known as ecstasy -- for post-traumatic stress disorder that were published in a scientific journal. The data in th...

2023-08-22 12:50:11 ET More on psychedelic drug companies Psychedelic Stocks = Super-Risky Biotechs Low On Cash. Make Small Bets. COMPASS: The Landscape Is Changing Quickly; Risk Is Up And Potential Down Psychedelic Stocks: Don't Bet On Just 1 Company Seelos:...

2023-08-14 01:03:21 ET Summary COMPASS Pathways continues to make solid progress in its ambition to gain regulatory approval for COMP360 psilocybin-assisted therapy for treatment-resistant depression. The group has refined its strategy for the eventual monetization of COMP360, and...

Numinus to Participate in a Water Tower Research Fireside Chat on Thursday, August 17, 2023 Canada NewsWire VANCOUVER, BC , Aug. 9, 2023 /CNW/ - Numinus Wellness Inc. ("Numinus" or the "Company") (TSX: NUMI) (OTCQX: NUMIF) – a mental health care ...

2023-07-26 08:45:24 ET Palm Beach, FL – July 26, 2023 – FinancialNewsMedia.com News Commentary – Psychedelic and hallucinogenic medicines market have been growing consistently over the past several years and are expected to continue to rise in the coming yea...